In the last three months, 8 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.88, with a high estimate of $12.00 and a low estimate of $9.00. This upward trend is evident, with the current average reflecting a 0.74% increase from the previous average price target of $10.80.
Decoding Analyst Ratings: A Detailed Look
The standing of G1 Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gil Blum | Needham | Maintains | Buy | $12.00 | $12.00 |
| Edward White | HC Wainwright & Co. | Maintains | Buy | $9.00 | $9.00 |
| Gil Blum | Needham | Maintains | Buy | $12.00 | $12.00 |
| Edward White | HC Wainwright & Co. | Maintains | Buy | $9.00 | $9.00 |
| Gil Blum | Needham | Maintains | Buy | $12.00 | $12.00 |
| Edward White | HC Wainwright & Co. | Maintains | Buy | $9.00 | - |
| Gil Blum | Needham | Maintains | Buy | $12.00 | - |
| Gil Blum | Needham | Maintains | Buy | $12.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to G1 Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of G1 Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of G1 Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into G1 Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on G1 Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About G1 Therapeutics
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Key Indicators: G1 Therapeutics's Financial Health
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: G1 Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 11.82%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: G1 Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -70.59%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): G1 Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -32.38%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): G1 Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -9.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.7, caution is advised due to increased financial risk.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.